文献速递乳腺癌

阿利塞替单药或联合氟维司群治疗内分泌耐药晚期乳腺癌的评估:2期TBCRC041随机临床试验

Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2023-01-01

这项2期随机临床试验纳入既往接受过氟维司群和CDK 4/6抑制剂的内分泌耐药、ERBB2阴性转移性乳腺癌绝经后女性,比较阿利塞替单药(第1组)与阿利塞替联合标准剂量氟维司群(第2组)的客观缓解率。结果显示第2组客观缓解率未较第1组提高至少20%,两组无进展生存期相近,阿利塞替单药在内分泌耐药和CDK 4/6抑制剂耐药患者中观察到有前景的临床活性,总体安全性可耐受。

要点

  • 第1组客观缓解率19.6%,第2组20.0%,联合氟维司群未提高客观缓解率。
  • 第1组中位无进展生存期5.6个月,第2组5.4个月,两组相近。
  • 阿利塞替单药在内分泌耐药和CDK 4/6抑制剂耐药转移性乳腺癌中观察到有前景的临床活性。

核心结论

  • 加用氟维司群未提高阿利塞替的客观缓解率或无进展生存期;阿利塞替单药在内分泌耐药和CDK 4/6抑制剂耐药的转移性乳腺癌中观察到有前景的临床活性,总体安全性可耐受。

研究设计与样本

  • 这项2期随机临床试验通过转化乳腺癌研究联盟开展,2017年7月至2019年11月入组。
  • 入组对象为既往接受过氟维司群的内分泌耐药、ERBB2阴性转移性乳腺癌绝经后女性。
  • 分层因素包括既往CDK 4/6抑制剂治疗、基线转移肿瘤ERα水平测量(<10%、≥10%)以及原发性或继发性内分泌耐药。
  • 114例预注册患者中96例(84.2%)注册,91例(79.8%)可评估主要终点。
  • 第1组接受阿利塞替50 mg口服,28天周期第1至3天、第8至10天、第15至17天每日给药;第2组接受相同剂量和方案的阿利塞替联合标准剂量氟维司群。

主要发现

  • 全部91例可评估患者(平均[SD]年龄58.5[11.3]岁;1例美洲印第安人/阿拉斯加原住民[1.1%]、2例亚洲人[2.2%]、6例黑人/非裔美国人[6.6%]、5例西班牙裔[5.5%]、79例白人[86.8%];第1组46例[50.5%],第2组45例[49.5%])均接受过CDK 4/6抑制剂治疗。
  • 客观缓解率第1组为19.6%(90% CI,10.6%-31.7%),第2组为20.0%(90% CI,10.9%-32.3%)。
  • 第1组24周临床获益率为41.3%(90% CI,29.0%-54.5%),中位无进展生存期为5.6个月(95% CI,3.9-10.0);第2组分别为28.9%(90% CI,18.0%-42.0%)和5.4个月(95% CI,3.9-7.8)。
  • 归因于阿利塞替的最常见3级或以上不良事件为中性粒细胞减少(41.8%)和贫血(13.2%)。
  • 因疾病进展停止治疗者第1组38例(82.6%)、第2组31例(68.9%);因毒性反应或拒绝停止治疗者第1组5例(10.9%)、第2组12例(26.7%)。

关键数值与推荐

  • 主要终点为当第1组预期客观缓解率为20%时,第2组客观缓解率较第1组提高至少20%。

临床怎么用

  • 作者认为,加用氟维司群未增加客观缓解率或无进展生存期,但阿利塞替单药在内分泌耐药和CDK 4/6抑制剂耐药的转移性乳腺癌中观察到有前景的临床活性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Aurora A kinase (AURKA) activation, related in part to AURKA amplification and variants, is associated with downregulation of estrogen receptor (ER) α expression, endocrine resistance, and implicated in cyclin-dependent kinase 4/6 inhibitor (CDK 4/6i) resistance. Alisertib, a selective AURKA inhibitor, upregulates ERα and restores endocrine sensitivity in preclinical metastatic breast cancer (MBC) models. The safety and preliminary efficacy of alisertib was demonstrated in early-phase trials; however, its activity in CDK 4/6i-resistant MBC is unknown. OBJECTIVE: To assess the effect of adding fulvestrant to alisertib on objective tumor response rates (ORRs) in endocrine-resistant MBC. DESIGN, SETTING, AND PARTICIPANTS: This phase 2 randomized clinical trial was conducted through the Translational Breast Cancer Research Consortium, which enrolled participants from July 2017 to November 2019. Postmenopausal women with endocrine-resistant, ERBB2 (formerly HER2)-negative MBC who were previously treated with fulvestrant were eligible. Stratification factors included prior treatment with CDK 4/6i, baseline metastatic tumor ERα level measurement (<10%, ≥10%), and primary or secondary endocrine resistance. Among 114 preregistered patients, 96 (84.2%) registered and 91 (79.8%) were evaluable for the primary end point. Data analysis began after January 10, 2022. INTERVENTIONS: Alisertib, 50 mg, oral, daily on days 1 to 3, 8 to 10, and 15 to 17 of a 28-day cycle (arm 1) or alisertib same dose/schedule with standard-dose fulvestrant (arm 2). MAIN OUTCOMES AND MEASURES: Improvement in ORR in arm 2 of at least 20% greater than arm 1 when the expected ORR for arm 1 was 20%. RESULTS: All 91 evaluable patients (mean [SD] age, 58.5 [11.3] years; 1 American Indian/Alaskan Native [1.1%], 2 Asian [2.2%], 6 Black/African American [6.6%], 5 Hispanic [5.5%], and 79 [86.8%] White individuals; arm 1, 46 [50.5%]; arm 2, 45 [49.5%]) had received prior treatment with CDK 4/6i. The ORR was 19.6%; (90% CI, 10.6%-31.7%) for arm 1 and 20.0% (90% CI, 10.9%-32.3%) for arm 2. In arm 1, the 24-week clinical benefit rate and median progression-free survival time were 41.3% (90% CI, 29.0%-54.5%) and 5.6 months (95% CI, 3.9-10.0), respectively, and in arm 2 they were 28.9% (90% CI, 18.0%-42.0%) and 5.4 months (95% CI, 3.9-7.8), respectively. The most common grade 3 or higher adverse events attributed to alisertib were neutropenia (41.8%) and anemia (13.2%). Reasons for discontinuing treatment were disease progression (arm 1, 38 [82.6%]; arm 2, 31 [68.9%]) and toxic effects or refusal (arm 1, 5 [10.9%]; arm 2, 12 [26.7%]). CONCLUSIONS AND RELEVANCE: This randomized clinical trial found that adding fulvestrant to treatment with alisertib did not increase ORR or PFS; however, promising clinical activity was observed with alisertib monotherapy among patients with endocrine-resistant and CDK 4/6i-resistant MBC. The overall safety profile was tolerable. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02860000.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Haddad TC, Suman VJ, D'Assoro AB, et al. Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial. JAMA Oncol. 2023. PMID: 36892847. doi:10.1001/jamaoncol.2022.7949

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。